Veterinary Medicines

Bovaclox DC Xtra Intramammary Suspension

Authorised
  • Ampicillin trihydrate
  • Cloxacillin hemibenzathine
Download as PDF

Product identification

Medicine name:
Bovaclox DC Xtra Intramammary Suspension
Active substance:
  • Ampicillin trihydrate
  • Cloxacillin hemibenzathine
Target species:
  • Cattle
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Ampicillin trihydrate
    346.45
    milligram(s)
    /
    1.00
    Syringe
  • Cloxacillin hemibenzathine
    1530.76
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle
      • Meat and offal
        28
        day
      • Milk
        156
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51CR50
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Available in:
  • Ireland
Package description:
  • Bovaclox DC Xtra is presented in high density polyethylene syringes (with high density polyethylene caps) containing 5.4g of an off-white non aqueous suspension. These intramammary syringes will be supplied in buckets of 120 syringes
  • Bovaclox DC Xtra is presented in high density polyethylene syringes (with high density polyethylene caps) containing 5.4g of an off-white non aqueous suspension. These intramammary syringes will be supplied in cartons of 24 syringes

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Norbrook Laboratories (Ireland) Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Norbrook Laboratories Limited
  • Norbrook Manufacturing Limited
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA22664/038/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 30/03/2025
Download